It is FDA’s job to make sure that a vaccine has meaningful benefits for the health and lives of most Americans, and especially those most at risk.
Read More »We’re Speaking Out on Health Issues
NCHR scientists and health policy experts provide written and oral statements on a wide range of topics.
Here are many of the ways we have been Speaking Out on Health Policy Issues for the last few years. Whether the topic is legislation intended to cure diseases, proposed bans on BPA or other chemicals that disrupt your hormones, the importance of including women, people of color, and patients over 65 in clinical trials, or many other topics, you’ll gain a better understanding of our evidence-based analyses by reading these letters, statements, and testimony.
Here are the ways we have been Speaking out on Medical Treatments and Products, such as prescription drugs and medical devices that the FDA is considering approving, or is considering taking off the market because of serious risks. Whether the topic is Chantix, Addyi, Yaz, Essure, or medical products you’ve never heard of, you can find out more about what is known and not known about the safety and effectiveness of a wide range of products by looking through this section of our website.
NCHR’s Comments USPSTF’s Draft Recommendation Statement Regarding Vitamin D Screening
The available evidence is still insufficient to assess the benefits and harms of vitamin D screening for asymptomatic adults.
Read More »FDA Warns Against Dental Amalgam Fillings for Children and Many Adults
Since the 1990s, patients with amalgam fillings have reported health problems that they believe are caused by their exposure to mercury. The amalgam is known to release small amounts of mercury over time, and while low levels of mercury vapor is not known to be harmful for most people, the long-term health risks of mercury inhalation are not clear.
Read More »NCHR’s Statement at FDA Advisory Committee Meeting on Olanzapine and Samidorphan Combination Tablets
Although patients may benefit from olanzapine/samidorphan by experiencing lower weight gain, the risks are too high to justify approval.
Read More »NCHR’s Testimony at FDA Advisory Committee Meeting on “Abuse-Deterrent” Amphetamine Sulfate Immediate-Release Oral Capsules
The drug should be labeled with an accurate description of its properties, not “abuse deterrent,” so that patients, family members, and healthcare providers do not erroneously assume the drug is less addictive.
Read More »